Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on Clozapine

Clinical Neuropharmacology

Volumn 21, Issue 4, 1998, Pages 245-250

  Spivak, Baruch ^a,b   Roitman, Susana ^a   Vered, Yaffa ^b,c   Mester, Roberto ^a,b   Graff, Eran ^a,b   Talmon, Yoram ^d,e   Guy, Nina ^b,d,e   Gonen, Noach ^a,b   Weizman, Abraham ^a,b,f  

^a NESS ZIONA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d KAPLAN HOSPITAL   (Israel)

^e HEBREW UNIVERSITY   (Israel)

^f GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

Aggression; Clozapine; Lipids; Norepinephrine; Schizophrenia; Serotonin

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; NORADRENALIN; TRIACYLGLYCEROL;

ADULT; AGGRESSION; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MENTAL DISEASE; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGGRESSION; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; CLOZAPINE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; SCHIZOPHRENIA; SEROTONIN; SUICIDE; TRIGLYCERIDES;

EID: 0031846072     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Yudofsky SC, Silver JM, Jackson W, Endicott J, William D. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 1986;143:35-9.
2. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-90.
3. Cooper SJ, Kelly CB, King DJ. 5-Hydroxindoleacetic acid in cerebrospinal fluid and prediction of suicidal behavior in schizophrenia. Lancet 1982;340:940-41.
4. Ringo DL, Lindley SE, Faull KF, Faustman WO. Cholesterol and serotonin: seeking a possible link between blood cholesterol and CSF 5-HIAA. Biol Psychiatry 1994;35:957-59.
5. Kunugi H, Takei N, Aoki H, Nanko S. Low serum cholesterol in suicide attempters. Biol Psychiatry 1997;41:196-200.
6. Boston PF, Dursun SM, Reveley MA. Cholesterol and mental disorder. Br J Psychiatry 1996;169:682-89.
7. Boston PF, Dursun SM, Zafar R, Reveley MA. Serum cholesterol and treatment-resistance in schizophrenia. Biol Psychiatry 1996;40: 542-43.
8. Spivak B, Mester R, Wittenberg N, Maman Z, Weizman A. Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients. Clin Neuropharmacology 1997;20:442-446.
9. First MB, Spitzer RL, Gibbon M, Williams JSW. Structured clinical interview for axis I DSM-IV disorders, patients version (SCID-P), Hebrew version. Tel Aviv: Jakobsohn, 1994.
10. Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1998;45:789-96.
11. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13: 261-76.
12. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
13. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
14. Plutchik R, van Praag HM. The measurement of suicidality, aggressivity and impulsivity. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:23-4.
15. Shoup RE, Keife J. Plasma catecholamines assayed conveniently and rapidly by LCEC. Current Separations 1980;3:1-30.
16. Tagari PC, Boullin DJ, Davies CL. Simplified determination of serotonin in plasma by liquid chromatography. Clin Chem 1984;30: 31-35.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972;18:499-502.
18. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen is a predictor of mortality in coronary heart desease patients. Arterioscler Tromb Vasc Biol 1996;16:351-56.
19. Naber D, Lepping M, Grohman R, Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients. Psychopharmacology (Berl) 1989;99(suppl):73-76.
20. Parsa M, Ramirez LF, Loula EC, Meltzer HY. Effect of clozapine on psychotic depression and Parkinsonism. J Clin Psychophrmacol 1991;11:330-31.
21. Floru L, Heinrich K, Wittek F. The problems of post-psychotic schizophrenic depressions and their pharmacological induction. Int Pharmacopsychiatry 1975;10:230-39.
22. Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A. Clozapine Treatment for Neuroleptic-Induced Tardive Dyskinesia, Parkinsonism, and Chronic Akathisia in Schizophrenic Patients. J Clin Psychiatry 1997;58:318-22.
23. Ghaeli P, Dufresne RL. Increased serum triglyceride levels in patients treated with clozapine. Int Pharmaceutical Abstr 1994;31: 2243.
24. Yamamoto BK, Pehek EA, Meltzer HY. Brain region effect of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 1994;55(suppl B):8-14.
25. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99(suppl):18-27.
26. Meltzer HY, Fatemi H. Suicide in schizophrenia: the effect if clozapine. Clin Neuropharmacology 1995;18(suppl):18-24.
27. Kahn RS, Davidson M, Siever L, Gabriel S, Apter S, Davis KL. Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry 1993;150:1337-42.
28. Gerlach J, Peacock L. New antipsychotics: the present status. Int Clin Psychopharmacology 1995;10(suppl 3):39-48.
29. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM. Do antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiat 1992;160(suppl 17):12-16.